Skip to main contentSkip to navigation
Sirius Investors

CTOR Stock: Citius Oncology, Inc. Stock Price, Analysis & Insights

Get live CTOR stock price $0.70, comprehensive Citius Oncology, Inc. stock analysis, charts, news, and expert forecast. Real-time CTOR stock data and investment insights.

0.70
2.75%Today
CTORCitius Oncology, Inc. • NASDAQ Global Market • Healthcare
Market Cap
65.09M
Volume
30.64K
52W High
6.19
52W Low
0.49

Loading chart data...

Investment Score

Annual (latest period)
Unavailable

A systematic tri-factor framework that integrates valuation, business quality, and market momentum into one investment signal. This helps investors triage opportunities faster, while surfacing risk regimes that may require tighter position sizing or deeper due diligence.

Score unavailable for this asset.

0-39

Defensive posture

40-54

Mixed / wait for confirmation

55-69

Constructive setup

70-100

Attractive zone

Total Score

Value

Cheapness vs fundamentals and cash generation

Quality

Durability of profitability and balance sheet

Momentum

Price trend strength and persistence

Professional usage: treat the score as a ranking and risk-filtering tool, then confirm with earnings revision trend, competitive positioning, and valuation relative to peers before capital allocation.

Company Overview

Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types. A key aspect of its pipeline includes the development of LYMPHIR, an investigational orphan drug intended to treat adults battling cu...

Company Information

CEO
Leonard L. Mazur
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
285

Contact Information

Address
420 Lexington Avenue
Country
US

Investment Analysis & Business Insights

Healthcare
Drug Manufacturers - General

Investment Highlights

Strong presence in the Healthcare sector with established market position

Higher growth potential with elevated volatility (Beta: 3.42)

Important Investment Considerations

  • All investments carry risk, including potential loss of principal for Citius Oncology, Inc. shareholders
  • Market volatility can significantly impact stock price, especially for smaller companies
  • Sector-specific risks in Healthcare may affect company performance
  • Past performance does not guarantee future results for Citius Oncology, Inc.
  • Investors should consider how Citius Oncology, Inc. fits within their overall portfolio allocation
  • Valuation metrics suggest potential, but require fundamental analysis

Market Cap

65.09M

P/E Ratio (TTM)

-1.46

Beta

3.42

Data Sources & Methodology

Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.

About Healthcare Sector

The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.